A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors-Reference-Cited by-同舟云学术

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

Published:2015-09-04 Issue:5 Volume:33 Page:1100-1107
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Jones Suzanne F.,Siu Lillian L.,Bendell Johanna C.,Cleary James M.,Razak Albiruni R. A.,Infante Jeffrey R.,Pandya Shuchi S.,Bedard Philippe L.,Pierce Kristen J.,Houk Brett,Roberts W. Gregory,Shreeve S. Martin,Shapiro Geoffrey I.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-015-0282-y.pdf

Reference37 articles.

1. Schwock J, Dhani N, Hedley DW (2010) Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 14:77–94. doi: 10.1517/14728220903460340

2. Schultze A, Fiedler W (2010) Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig Drugs 19:777–788. doi: 10.1517/13543784.2010.489548

3. Schlaepfer DD, Mitra SK, Ilic D (2004) Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692:77–102. doi: 10.1016/j.bbamcr.2004.04.008

4. Hao H, Naomoto Y, Bao X et al (2009) Focal adhesion kinase as potential target for cancer therapy (Review). Oncol Rep 22:973–979

5. Tilghman RW, Parsons JT (2008) Focal adhesion kinase as a regulator of cell tension in the progression of cancer. Semin Cancer Biol 18:45–52. doi: 10.1016/j.semcancer.2007.08.002

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics;Targeted Oncology;2024-09-13

2. Exosomal CTHRC1 from cancer-associated fibroblasts facilitates endometrial cancer progression via ITGB3/FAK signaling pathway;Heliyon;2024-08

3. Defactinib inhibits FAK phosphorylation and regulates psoriasis via attenuating hyperproliferation of keratinocytes;The Journal of Dermatology;2024-07-25

4. Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities;Journal of Cell Science;2024-07-15

5. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders;Biochemical Pharmacology;2024-06